• World News
  • Politics
  • Stock
  • Investing
  • Editor’s Pick
Time And Sales Reporter
Editor's Pick

Elon Musk’s Neuralink raises $650 million in fresh capital

by admin June 4, 2025
June 4, 2025

Elon Musk’s brain tech startup Neuralink has closed a $650 million funding round, the company announced Monday.

ARK Invest, Founders Fund, Sequoia Capital, Thrive Capital, Lightspeed Venture Partners and other firms participated in the round, according to a press release. Neuralink said the fresh capital will help the company bring its technology to more patients and develop new devices that “deepen the connection between biological and artificial intelligence.”

Neuralink is building a brain-computer interface, or BCI, which is a system that translates brain signals into commands for external technologies.

The company’s first system, called Telepathy, involves 64 “threads” that are inserted directly into the brain. The threads are thinner than a human hair and record neural signals through 1,024 electrodes, according to Neuralink’s website.

The initial aim of the technology is to help patients with severe paralysis restore some independence. As of Monday, five patients have been implanted with Neuralink’s technology, and are able to “control digital and physical devices with their thoughts,” the release said.

Neuralink is currently carrying out four separate clinical trials around its Telepathy system.

BCIs have been studied in academia for decades, and several other companies, including Synchron, Paradromics and Precision Neuroscience, are developing their own systems.

Paradromics on Monday announced it successfully implanted its BCI in a human for the first time.

It’s not clear what devices Neuralink will look to develop next, but Musk has for years espoused grand ambitions for the brain tech startup. He has even claimed that he would be willing to get an implant himself.

One of the capabilities Musk has repeatedly highlighted is the ability to restore vision to blind patients.

Neuralink received a “Breakthrough Device” designation from the U.S. Food and Drug Administration for a device called Blindsight. This designation is granted to medical devices that have the potential to provide improved treatment for debilitating or life-threatening conditions.

In a post on his social media platform X in September, Musk said Blindsight will enable even those who have lost both eyes and their optic nerve to see.

Neuralink still has a long road ahead before it can commercialize these technologies.

This post appeared first on NBC NEWS

previous post
Tesla’s robotaxi launch in tech-friendly Austin has Musk playing catch-up in his hometown
next post
Scoping Study Demonstrates Low Cost Potential (Replacement)

Related Posts

LimeWire acquires Fyre Festival, asking ‘What Could Possibly...

September 17, 2025

Convenience stores are eating fast-food chains’ breakfast

September 16, 2025

Trump administration ramps up pressure on Labor Department...

September 12, 2025

Kenvue stock drops 10% on report RFK Jr....

September 9, 2025

Mortgage rates see biggest one-day drop in over...

September 6, 2025

Paramount mandates 5-day-a-week return to office ahead of...

September 5, 2025







    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.




    Recent Posts

    • LimeWire acquires Fyre Festival, asking ‘What Could Possibly Go Wrong?’

      September 17, 2025
    • Bondi ‘hate speech’ remarks spark torrent of criticism from conservatives

      September 17, 2025
    • Hakeem Jeffries’ 4-word answer to why he skipped Charlie Kirk vigil

      September 17, 2025
    • Trump assassination attempt trial continues with more FBI testimony after rifle called ‘prepared to fire’

      September 17, 2025
    • Patel defends FBI pull-up test after Hirono decries it as gender bias in Senate showdown

      September 17, 2025
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 timeandsalesreporter.com | All Rights Reserved

    Time And Sales Reporter
    • World News
    • Politics
    • Stock
    • Investing
    • Editor’s Pick

    Read alsox

    Trump’s Sharp-Elbowed Europe Strategy Is Producing Results

    March 19, 2025

    Your Body Is Not Government Property

    April 8, 2025

    Kenvue stock drops 10% on report RFK Jr....

    September 9, 2025